{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:45:47Z","timestamp":1785797147860,"version":"3.56.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03666-x","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:27:24Z","timestamp":1760524044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinicopathological characteristics of BRCA1-associated breast carcinoma patients in Kazakhstan"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-8212","authenticated-orcid":false,"given":"Ainur","family":"Samigatova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-1462","authenticated-orcid":false,"given":"Nursulu","family":"Altaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2629-7164","authenticated-orcid":false,"given":"Yerlan","family":"Suleimenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2552-0323","authenticated-orcid":false,"given":"Petr","family":"Sibiryakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-5132","authenticated-orcid":false,"given":"Kuantkan","family":"Zhabagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4943-1980","authenticated-orcid":false,"given":"Zhanar","family":"Zhakypbekkyzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4931-6935","authenticated-orcid":false,"given":"Bakhytzhan","family":"Seksenbaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"3","key":"3666_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3666_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"key":"3666_CR3","doi-asserted-by":"crossref","unstructured":"Kaidarova D, Shatkovskaya O, Ongarbayev B, Zhylkaidarova A, Seisenbayeva G, Lavrentyeva I, et al. Indicators of the oncology service of the republic of Kazakhstan, 2023 (statistical and analytical materials). JSC Kazakh institute of oncology and radiologyat the ministry of healthcare of the republic of Kazakhstan; 2024.","DOI":"10.52532\/20-09-2024-1-410"},{"issue":"1","key":"3666_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/cancers17010039","volume":"17","author":"RM Plesea","year":"2024","unstructured":"Plesea RM, Riza AL, Ahmet AM, Gavril\u0103 I, Mitut A, Camen GC, et al. Clinically significant BRCA1 and BRCA2 germline variants in breast Cancer\u2014A Single-Center experience. Cancers (Basel). 2024;17(1):39.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3666_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12920-019-0545-0","volume":"12","author":"A Lal","year":"2019","unstructured":"Lal A, Ramazzotti D, Weng Z, Liu K, Ford JM, Sidow A. Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. BMC Med Genomics. 2019;12(1):84.","journal-title":"BMC Med Genomics"},{"key":"3666_CR6","doi-asserted-by":"crossref","unstructured":"Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1 controls Homology-Directed DNA repair. Mol Cell. 1999;4(4):511\u20138.","DOI":"10.1016\/S1097-2765(00)80202-6"},{"issue":"2","key":"3666_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","volume":"7","author":"ME Moynahan","year":"2001","unstructured":"Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for Homology-Directed repair of chromosomal breaks. Mol Cell. 2001;7(2):263\u201372.","journal-title":"Mol Cell"},{"issue":"3","key":"3666_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62(3):676\u201389.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"3666_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng0495-444","volume":"9","author":"ME Thompson","year":"1995","unstructured":"Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 1995;9(4):444\u201350.","journal-title":"Nat Genet"},{"issue":"10","key":"3666_CR10","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S","volume":"85","author":"S Noguchi","year":"1999","unstructured":"Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer. 1999;85(10):2200\u20135.","journal-title":"Cancer"},{"issue":"9064","key":"3666_CR11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(96)10109-4","volume":"349","author":"MR Stratton","year":"1997","unstructured":"Stratton MR. Pathology of Familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349(9064):1505\u201310.","journal-title":"Lancet"},{"issue":"11","key":"3666_CR12","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1200\/JCO.1999.17.11.3653","volume":"17","author":"KA Phillips","year":"1999","unstructured":"Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol. 1999;17(11):3653\u201363.","journal-title":"J Clin Oncol"},{"key":"3666_CR13","doi-asserted-by":"crossref","unstructured":"Incorvaia L, Fanale D, Bono M, Cal\u00f2 V, Fiorino A, Brando C et al. BRCA1\/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype\u2013phenotype correlation in a cohort of 531 patients. Ther Adv Med Oncol. 2020;12.","DOI":"10.1177\/1758835920975326"},{"issue":"3","key":"3666_CR14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/0008-5472.822.65.3","volume":"65","author":"EH van Beers","year":"2005","unstructured":"van Beers EH, van Welsem T, Wessels LFA, Li Y, Oldenburg RA, Devilee P, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 2005;65(3):822\u20137.","journal-title":"Cancer Res"},{"issue":"9","key":"3666_CR15","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"SR Lakhani","year":"2002","unstructured":"Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of Familial breast cancer: predictive value of immunohistochemical markers Estrogen Receptor, progesterone Receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310\u20138.","journal-title":"J Clin Oncol"},{"issue":"23","key":"3666_CR16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, Ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402.","journal-title":"JAMA"},{"issue":"9","key":"3666_CR17","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3390\/cancers12092415","volume":"12","author":"D Fanale","year":"2020","unstructured":"Fanale D, Incorvaia L, Filorizzo C, Bono M, Fiorino A, Cal\u00f2 V, et al. Detection of germline mutations in a cohort of 139 patients with bilateral breast cancer by Multi-Gene panel testing: impact of pathogenic variants in other genes beyond BRCA1\/2. Cancers (Basel). 2020;12(9):2415.","journal-title":"Cancers (Basel)"},{"key":"3666_CR18","unstructured":"Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, CANCER RESEARCH. Distinct Molecular Pathogeneses of Early-Onset Breast Cancers in BRCA1 and BRCA2 Mutation Carriers: A Population-based Study 1 [Internet]. Vol. 59. 2011. Available from: http:\/\/aacrjournals.org\/cancerres\/article-pdf\/59\/8\/2011\/3246219\/ch089902011o.pdf."},{"issue":"1","key":"3666_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1 \/ 2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134\u201347.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"3666_CR20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. JNCI: J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"3666_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.critrevonc.2006.01.006","volume":"59","author":"E Honrado","year":"2006","unstructured":"Honrado E, Ben\u00edtez J, Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol. 2006;59(1):27\u201339.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"36","key":"3666_CR22","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1200\/JCO.2009.27.2294","volume":"28","author":"AJ Rijnsburger","year":"2010","unstructured":"Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MMA, Boetes C, Loo CE, et al. BRCA1 -Associated breast cancers present differently from BRCA2 -Associated and Familial cases: Long-Term Follow-Up of the Dutch MRISC screening study. J Clin Oncol. 2010;28(36):5265\u201373.","journal-title":"J Clin Oncol"},{"issue":"20","key":"3666_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJM199705153362003","volume":"336","author":"M Krainer","year":"1997","unstructured":"Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, et al. Differential contributions of BRCA1 and BRCA2 to Early-Onset breast cancer. N Engl J Med. 1997;336(20):1416\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"3666_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clbc.2019.08.003","volume":"20","author":"E Fountzilas","year":"2020","unstructured":"Fountzilas E, Konstantopoulou I, Vagena A, Apostolou P, Papadimitriou C, Christodoulou C, et al. Pathology of BRCA1- and BRCA2-associated breast cancers: known and less known connections. Clin Breast Cancer. 2020;20(2):152\u20139.","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"3666_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","volume":"43","author":"CTM Brekelmans","year":"2007","unstructured":"Brekelmans CTM, Tilanus-Linthorst MMA, Seynaeve C, vd Ouweland A, Menke-Pluymers MBE, Bartels CCM, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1\/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43(5):867\u201376.","journal-title":"Eur J Cancer"},{"key":"3666_CR26","doi-asserted-by":"crossref","unstructured":"Bolton KL. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA. 2012;307(4):382.","DOI":"10.1001\/jama.2012.20"},{"issue":"3","key":"3666_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/annonc\/mdj095","volume":"17","author":"CTM Brekelmans","year":"2006","unstructured":"Brekelmans CTM, Seynaeve C, Menke-Pluymers M, Br\u00fcggenwirth HT, Tilanus-Linthorst MMA, Bartels CCM, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol. 2006;17(3):391\u2013400.","journal-title":"Ann Oncol"},{"issue":"24","key":"3666_CR28","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1200\/JCO.2000.18.24.4053","volume":"18","author":"D Stoppa-Lyonnet","year":"2000","unstructured":"Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol. 2000;18(24):4053\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3666_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of Poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.","journal-title":"N Engl J Med"},{"key":"3666_CR30","doi-asserted-by":"crossref","unstructured":"Foulkes WD. Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. CancerSpectrum Knowl Environ. 2003;95(19):1482\u20135.","DOI":"10.1093\/jnci\/djg050"},{"issue":"1","key":"3666_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12253-008-9090-4","volume":"15","author":"R Bori","year":"2009","unstructured":"Bori R, Cserni G. Basal phenotype in breast carcinoma occurring in women aged 35 or younger. Pathol Oncol Res. 2009;15(1):41\u20135.","journal-title":"Pathol Oncol Res"},{"issue":"26","key":"3666_CR32","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA -Positive and BRCA -Negative breast cancer. J Clin Oncol. 2008;26(26):4282\u20138.","journal-title":"J Clin Oncol"},{"key":"3666_CR33","doi-asserted-by":"crossref","unstructured":"S\u00f8rlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci. 2003;100(14):8418\u201323.","DOI":"10.1073\/pnas.0932692100"},{"issue":"6","key":"3666_CR34","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1186\/s13058-014-0474-y","volume":"16","author":"AB Spurdle","year":"2014","unstructured":"Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, et al. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014;16(6):3419.","journal-title":"Breast Cancer Res"},{"key":"3666_CR35","unstructured":"Stoppa-Lyonnet D. Article in Cancer Research [Internet]. 1996. Available from: https:\/\/www.researchgate.net\/publication\/14635482."},{"issue":"1","key":"3666_CR36","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/bcr2478","volume":"12","author":"N Tung","year":"2010","unstructured":"Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010;12(1):R12.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"3666_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: American society of clinical Oncology\/College of American pathologists guideline update. Arch Pathol Lab Med. 2020;144(5):545\u201363.","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"3666_CR38","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364\u201382.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"3666_CR39","first-page":"405","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Sci. 2015;17(5):405\u201324.","journal-title":"Genet Sci"},{"key":"3666_CR40","doi-asserted-by":"crossref","unstructured":"Tilanus-Linthorst MMA, Obdeijn IM, Hop WCJ, Causer PA, Leach MO, Warner E et al. BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials. Clin Cancer Res. 2007;13(24):7357\u201362.","DOI":"10.1158\/1078-0432.CCR-07-0689"},{"issue":"2","key":"3666_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cncr.26284","volume":"118","author":"JK Litton","year":"2012","unstructured":"Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric\u2010Bernstam F, et al. Earlier age of onset of BRCA mutation\u2010related cancers in subsequent generations. Cancer. 2012;118(2):321\u20135.","journal-title":"Cancer"},{"issue":"6","key":"3666_CR42","first-page":"2364","volume":"24","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Li Y, Zhang X, Qiu J, Pang T, Huang L. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis. JBUON. 2019;24(6):2364\u201371.","journal-title":"JBUON"},{"issue":"6","key":"3666_CR43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/95.6.448","volume":"95","author":"GS Dite","year":"2003","unstructured":"Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MRE, et al. Familial Risks, Early-Onset breast Cancer, and BRCA1 and BRCA2 germline mutations. JNCI J Natl Cancer Inst. 2003;95(6):448\u201357.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"3666_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10549-023-06946-8","volume":"199","author":"MB Daly","year":"2023","unstructured":"Daly MB, Rosenthal E, Cummings S, Bernhisel R, Kidd J, Hughes E, et al. The association between age at breast cancer diagnosis and prevalence of pathogenic variants. Breast Cancer Res Treat. 2023;199(3):617\u201326.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3666_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10549-022-06702-4","volume":"195","author":"F Zang","year":"2022","unstructured":"Zang F, Ding X, Chen J, Hu L, Sun J, Zhang J, et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype. Breast Cancer Res Treat. 2022;195(3):431\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"3666_CR46","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.20.01200","volume":"39","author":"PA Fasching","year":"2021","unstructured":"Fasching PA, Yadav S, Hu C, Wunderle M, H\u00e4berle L, Hart SN, et al. Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer \u2014Association with patient and disease characteristics and effect on prognosis. J Clin Oncol. 2021;39(15):1619\u201330.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3666_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","volume":"22","author":"J O\u2019Shaughnessy","year":"2020","unstructured":"O\u2019Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, et al. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020;22(1):114.","journal-title":"Breast Cancer Res"},{"issue":"14","key":"3666_CR48","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1002\/cncr.25911","volume":"117","author":"LJ Lee","year":"2011","unstructured":"Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. 2011;117(14):3093\u2013100.","journal-title":"Cancer"},{"issue":"14","key":"3666_CR49","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO-24-01334","volume":"43","author":"M Lambertini","year":"2025","unstructured":"Lambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, et al. Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status. J Clin Oncol. 2025;43(14):1706\u201319.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"3666_CR50","doi-asserted-by":"publisher","first-page":"S706","DOI":"10.4103\/jcrt.jcrt_639_22","volume":"19","author":"PS Soman","year":"2023","unstructured":"Soman PS, Hemalatha A, Sreeramulu PN. Expression of BRCA1 by immunohistochemistry and its association with ER, PR, Her2neu status in infiltrative ductal carcinoma of breast. J Cancer Res Ther. 2023;19(Suppl 2):S706\u201311.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"3666_CR51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4274\/ejbh.galenos.2020.6346","volume":"17","author":"MM Atc\u0131","year":"2021","unstructured":"Atc\u0131 MM, Geredeli \u00c7, Ay S, Sakin A, Ert\u00fcrk B, Se\u00e7meler \u015e, et al. Clinical and pathological characteristics of patients with High-Risk breast cancer based on BRCA mutation profiles: A retrospective study. Eur J Breast Health. 2021;17(2):123\u20137.","journal-title":"Eur J Breast Health"},{"issue":"1","key":"3666_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1471-2407-10-145","volume":"10","author":"MR van Heerma","year":"2010","unstructured":"van Heerma MR, van der Groep P, Bart J, van der Wall E, van Diest PJ. Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls. BMC Cancer. 2010;10(1):145.","journal-title":"BMC Cancer"},{"issue":"2","key":"3666_CR53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncr.32540","volume":"126","author":"Y Song","year":"2020","unstructured":"Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU. Patterns of recurrence and metastasis in BRCA1\/BRCA2 -associated breast cancers. Cancer. 2020;126(2):271\u201380.","journal-title":"Cancer"},{"issue":"1","key":"3666_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41598-021-03471-w","volume":"12","author":"HJ Chang","year":"2022","unstructured":"Chang HJ, Yang UC, Lai MY, Chen CH, Fann YC. High BRCA1 gene expression increases the risk of early distant metastasis in ER\u2009+\u2009breast cancers. Sci Rep. 2022;12(1):77.","journal-title":"Sci Rep"},{"issue":"10","key":"3666_CR55","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1245\/s10434-014-3904-2","volume":"21","author":"SF Noori","year":"2014","unstructured":"Noori SF, Gangi A, Nelson ME, Choi M, Mirzadehgan P, Bonk AK, et al. Comparison of nodal metastasis between BRCA mutation carriers and Non-BRCA mutation carriers with breast cancer. Ann Surg Oncol. 2014;21(10):3324\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"3666_CR56","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1054\/bjoc.2001.2103","volume":"85","author":"GH de Bock","year":"2001","unstructured":"de Bock GH, Tollenaar RAEM, Papelard H, Cornelisse CJ, Devilee P, van de Vijver MJ. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer. 2001;85(9):1347\u201350.","journal-title":"Br J Cancer"},{"issue":"4","key":"3666_CR57","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5","volume":"18","author":"PO Chappuis","year":"2000","unstructured":"Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol. 2000;18(4):287\u201395.","journal-title":"Semin Surg Oncol"},{"key":"3666_CR58","doi-asserted-by":"crossref","unstructured":"Bujassoum SM, Bugrein HA, Sulaiman R Al. Genotype and phenotype correlation of breast cancer in BRCA mutation carriers and Non-Carriers. J Cancer Sci Ther. 2017;09(03).","DOI":"10.4172\/1948-5956.1000442"},{"key":"3666_CR59","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2147\/CMAR.S348529","volume":"14","author":"S Stella","year":"2022","unstructured":"Stella S, Vitale SR, Martorana F, Massimino M, Pavone G, Lanzafame K, et al. Mutational analysis of BRCA1 and BRCA2 genes in breast cancer patients from Eastern Sicily. Cancer Manag Res. 2022;14:1341\u201352.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"3666_CR60","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-03-1061","volume":"10","author":"WD Foulkes","year":"2004","unstructured":"Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1 - and BRCA2 -Related breast cancer. Clin Cancer Res. 2004;10(6):2029\u201334.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3666_CR61","doi-asserted-by":"publisher","first-page":"e57581","DOI":"10.1371\/journal.pone.0057581","volume":"8","author":"DM Carraro","year":"2013","unstructured":"Carraro DM, Koike Folgueira MAA, Garcia Lisboa BC, Ribeiro Olivieri EH, Vitorino Krepischi AC, de Carvalho AF, et al. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: A portrait of Early-Onset breast cancer in Brazil. PLoS ONE. 2013;8(3):e57581.","journal-title":"PLoS ONE"},{"issue":"5","key":"3666_CR62","doi-asserted-by":"publisher","first-page":"e64268","DOI":"10.1371\/journal.pone.0064268","volume":"8","author":"MJ Larsen","year":"2013","unstructured":"Larsen MJ, Kruse TA, Tan Q, L\u00e6nkholm AV, Bak M, Lykkesfeldt AE, et al. Classifications within molecular subtypes enables identification of BRCA1\/BRCA2 mutation carriers by RNA tumor profiling. PLoS ONE. 2013;8(5):e64268.","journal-title":"PLoS ONE"},{"issue":"1","key":"3666_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3892\/ol.2022.13340","volume":"24","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Gao W. Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer (Review). Oncol Lett. 2022;24(1):219.","journal-title":"Oncol Lett"},{"issue":"5","key":"3666_CR64","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117\u201330.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"3666_CR65","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-012-2021-9","volume":"134","author":"F Fostira","year":"2012","unstructured":"Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic cooperative oncology group study. Breast Cancer Res Treat. 2012;134(1):353\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"3666_CR66","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","volume":"11","author":"SR Lakhani","year":"2005","unstructured":"Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using Estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175\u201380.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"3666_CR67","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1200\/JCO.2010.33.6446","volume":"29","author":"E Lee","year":"2011","unstructured":"Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, et al. Characteristics of Triple-Negative breast cancer in patients with a BRCA1 mutation: results from a Population-Based study of young women. J Clin Oncol. 2011;29(33):4373\u201380.","journal-title":"J Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03666-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:08:14Z","timestamp":1760526494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03666-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3666"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03666-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"1899"}}